ArticleWorld journal of radiology2026
Portal vein embolization for arterio-portal shunt closure in hepatocellular carcinoma to facilitate selective internal radiation therapy.
Article in World journal of radiology, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
8 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
backgroundSelective internal radiation therapy (SIRT) has been widely used in the treatment of hepatocellular carcinoma (HCC). However, marked intrahepatic shunt (IHS) secondary to arterio-portal shunt (APS) often precludes safe SIRT administration.
aimTo evaluate the efficacy and safety of portal vein embolization (PVE) in reducing IHS and enabling SIRT therapy in HCC patients with APS.
methodsThis retrospective study enrolled seven HCC patients with APS confirmed by hepatic angiography during mapping. PVE was performed to close the APS outlet and single photon emission computed tomography/computed tomography was performed to determine the distribution of (99m) technetium-labeled macroaggregated albumin. These patients meeting the criteria for SIRT subsequently underwent Yttrium-90 (Y-90) resin microspheres administration. Changes in liver function and complications were monitored during the 6-month follow-up period.
resultsComplete APS occlusion was achieved in six patients (
conclusionPVE is a safe and effective strategy to reduce IHS in HCC patients with APS, thereby improving eligibility for SIRT.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.